famotidine has been researched along with Malignant Melanoma in 11 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Outpatient intravenous IL-2 and famotidine has activity in melanoma." | 7.78 | Outpatient intravenous interleukin-2 with famotidine has activity in metastatic melanoma. ( Johnson, E; Perez, M; Quan, FM; Quan, WD, 2012) |
| " It has been previously shown that the patients with metastatic melanoma or kidney cancer may be treated safely with pulse IL-2 daily for 5 days preceded by intravenous famotidine." | 7.77 | Pulse interleukin-2 with famotidine induces CD56+ lymphocytes in the peripheral blood of patients with metastatic melanoma or kidney cancer. ( Gagnon, GA; Quan, FM; Quan, WD; Walker, PR, 2011) |
| "Famotidine may increase LAK cytotoxicity against neoplastic cells by allowing for greater IL-2 uptake at the IL-2 receptor on lymphocytes." | 6.74 | Activity of continuous infusion + pulse interleukin-2 with famotidine in metastatic melanoma. ( Quan, FM; Quan, WD, 2009) |
| "Famotidine may enhance the activity of T-cells further by allowing for increased IL-2 internalization by the IL-2 receptor on lymphocytes." | 5.36 | Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma. ( Knupp, C; Quan, F; Quan, W; Walker, P, 2010) |
| "Famotidine may increase LAK activity by increasing IL-2 internalization by the IL-2 receptor on lymphocytes." | 5.35 | High-dose intensity pulse interleukin-2 with famotidine has activity in metastatic melanoma. ( King, LA; Liles, DK; Picton, M; Quan, FM; Quan, WD; Tyre, C; Walker, PR, 2008) |
| "Famotidine may increase IL-2 internalization by the IL-2 receptor on T-lymphocytes." | 5.35 | Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer. ( King, LA; Quan, FM; Quan, WD; Walker, PR, 2008) |
| "Two (2) patients with kidney cancer have been converted to complete responders with resection of residual disease, remaining without relapse at 5+ and 20+ months." | 5.33 | Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2. ( Elsamaloty, HM; Ghai, V; Liles, DK; Quan, FM; Quan, WD; Ramirez, M; Vinogradov, M; Walker, PR, 2006) |
| "Famotidine may enhance the lysis of tumors by cytotoxic lymphocytes." | 5.32 | High-dose continuous infusion plus pulse interleukin-2 and famotidine in melanoma. ( Jackson, S; Khan, N; Quan, W; Ramirez, M; Taylor, WC; Vinogradov, M, 2004) |
| "High-dose, continuous-infusion interleukin-2 (IL-2) followed by pulse dose and concurrent administration of famotidine has demonstrated response rates of 64% and 33% in patients with metastatic melanoma and metastatic renal cell carcinoma, respectively." | 4.84 | Nursing care of patients receiving high-dose, continuous-infusion interleukin-2 with pulse dose and famotidine. ( Quan, W; Tyre, CC, 2007) |
| " Outpatient intravenous IL-2 and famotidine has activity in melanoma." | 3.78 | Outpatient intravenous interleukin-2 with famotidine has activity in metastatic melanoma. ( Johnson, E; Perez, M; Quan, FM; Quan, WD, 2012) |
| " It has been previously shown that the patients with metastatic melanoma or kidney cancer may be treated safely with pulse IL-2 daily for 5 days preceded by intravenous famotidine." | 3.77 | Pulse interleukin-2 with famotidine induces CD56+ lymphocytes in the peripheral blood of patients with metastatic melanoma or kidney cancer. ( Gagnon, GA; Quan, FM; Quan, WD; Walker, PR, 2011) |
| "Famotidine may increase LAK cytotoxicity against neoplastic cells by allowing for greater IL-2 uptake at the IL-2 receptor on lymphocytes." | 2.74 | Activity of continuous infusion + pulse interleukin-2 with famotidine in metastatic melanoma. ( Quan, FM; Quan, WD, 2009) |
| "Famotidine may enhance the activity of T-cells further by allowing for increased IL-2 internalization by the IL-2 receptor on lymphocytes." | 1.36 | Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma. ( Knupp, C; Quan, F; Quan, W; Walker, P, 2010) |
| "Famotidine may increase LAK activity by increasing IL-2 internalization by the IL-2 receptor on lymphocytes." | 1.35 | High-dose intensity pulse interleukin-2 with famotidine has activity in metastatic melanoma. ( King, LA; Liles, DK; Picton, M; Quan, FM; Quan, WD; Tyre, C; Walker, PR, 2008) |
| "Famotidine may increase IL-2 internalization by the IL-2 receptor on T-lymphocytes." | 1.35 | Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer. ( King, LA; Quan, FM; Quan, WD; Walker, PR, 2008) |
| "Two (2) patients with kidney cancer have been converted to complete responders with resection of residual disease, remaining without relapse at 5+ and 20+ months." | 1.33 | Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2. ( Elsamaloty, HM; Ghai, V; Liles, DK; Quan, FM; Quan, WD; Ramirez, M; Vinogradov, M; Walker, PR, 2006) |
| "Famotidine may enhance the lysis of tumors by cytotoxic lymphocytes." | 1.32 | High-dose continuous infusion plus pulse interleukin-2 and famotidine in melanoma. ( Jackson, S; Khan, N; Quan, W; Ramirez, M; Taylor, WC; Vinogradov, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (72.73) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Quan, WD | 7 |
| Walker, PR | 5 |
| Picton, M | 1 |
| Quan, FM | 7 |
| King, LA | 2 |
| Tyre, C | 1 |
| Liles, DK | 3 |
| Quan, W | 4 |
| Knupp, C | 1 |
| Quan, F | 2 |
| Walker, P | 2 |
| Gagnon, GA | 1 |
| Perez, M | 1 |
| Johnson, E | 1 |
| Ramirez, M | 3 |
| Taylor, WC | 1 |
| Vinogradov, M | 3 |
| Khan, N | 2 |
| Jackson, S | 1 |
| Taylor, C | 1 |
| Elsamaloty, HM | 1 |
| Ghai, V | 1 |
| Milligan, KS | 1 |
| Cuenca, RE | 1 |
| Tyre, CC | 1 |
1 review available for famotidine and Malignant Melanoma
| Article | Year |
|---|---|
Nursing care of patients receiving high-dose, continuous-infusion interleukin-2 with pulse dose and famotidine.
Topics: Anti-Ulcer Agents; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Drug | 2007 |
3 trials available for famotidine and Malignant Melanoma
| Article | Year |
|---|---|
Activity of continuous infusion + pulse interleukin-2 with famotidine in metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Famotidine; Fema | 2009 |
Administration of high-dose continuous infusion interleukin-2 to patients age 70 or over.
Topics: Adenosine; Aged; Aged, 80 and over; Aging; Capillary Leak Syndrome; Famotidine; Hemodynamics; Humans | 2005 |
Continuous infusion interleukin-2 and intravenous famotidine in metastatic melanoma.
Topics: Adult; Aged; Drug Therapy, Combination; Famotidine; Female; Humans; Infusions, Intravenous; Interleu | 2006 |
7 other studies available for famotidine and Malignant Melanoma
| Article | Year |
|---|---|
High-dose intensity pulse interleukin-2 with famotidine has activity in metastatic melanoma.
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Disease Progression; Famotidine; Female; Humans; | 2008 |
Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cycl | 2010 |
Pulse interleukin-2 with famotidine induces CD56+ lymphocytes in the peripheral blood of patients with metastatic melanoma or kidney cancer.
Topics: CD56 Antigen; Famotidine; Humans; Infusions, Intravenous; Interleukin-2; Kidney Neoplasms; Killer Ce | 2011 |
Outpatient intravenous interleukin-2 with famotidine has activity in metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Famotidine; Female; | 2012 |
High-dose continuous infusion plus pulse interleukin-2 and famotidine in melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Drug Therapy, Combination; Famotidine; Female; H | 2004 |
Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2.
Topics: Aged; Drug Administration Schedule; Drug Synergism; Famotidine; Female; Humans; Immunotherapy; Infus | 2006 |
Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Cycloph | 2008 |